Ken Griffin C4 Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$4.05 - $8.1 $184,275 - $368,550	-45,500 Reduced 29.45%	109,000 $503,000
Q1 2024 May 15, 2024	SELL	$5.3 - $11.0 $309,520 - $642,400	-58,400 Reduced 27.43%	154,500 $1.26 Million
Q4 2023 Feb 14, 2024	BUY	$1.18 - $6.03 $232,696 - $1.19 Million	197,200 Added 1256.05%	212,900 $1.2 Million
Q3 2023 Nov 14, 2023	BUY	$1.81 - $3.89 $24,978 - $53,682	13,800 Added 726.32%	15,700 $29,000
Q2 2023 Aug 14, 2023	SELL	$2.75 - $3.77 $1,650 - $2,262	-600 Reduced 24.0%	1,900 $5,000
Q1 2023 May 15, 2023	SELL	$3.1 - $9.02 $3,100 - $9,020	-1,000 Reduced 28.57%	2,500 $7,000
Q4 2022 Feb 14, 2023	BUY	$5.42 - $10.24 $18,970 - $35,840	3,500 New	3,500 $20,000

127

53.8M

331K

145K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $292M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.